These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 17581316

  • 1. Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
    Yoshida C, Niiya K, Niiya M, Shibakura M, Asaumi N, Tanimoto M.
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):425-33. PubMed ID: 17581316
    [Abstract] [Full Text] [Related]

  • 2. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
    Niiya M, Niiya K, Shibakura M, Asaumi N, Yoshida C, Shinagawa K, Teshima T, Ishimaru F, Ikeda K, Tanimoto M.
    Oncology; 2004 Jul; 67(3-4):310-9. PubMed ID: 15557793
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 4. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW.
    Mol Cancer Ther; 2004 May 01; 3(5):527-35. PubMed ID: 15141010
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H, Igishi T, Ueda Y, Shigeoka Y, Kodani M, Morita M, Takeda K, Sumikawa T, Nakazaki H, Matsunami K, Matsumoto S, Shimizu E.
    Oncol Rep; 2010 Jan 01; 23(1):217-22. PubMed ID: 19956885
    [Abstract] [Full Text] [Related]

  • 6. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW, Honsawek S, Litz J, Buchdunger E.
    Clin Cancer Res; 2000 Aug 01; 6(8):3319-26. PubMed ID: 10955819
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
    Smith PC, Santibañez JF, Morales JP, Martinez J.
    J Periodontal Res; 2004 Dec 01; 39(6):380-7. PubMed ID: 15491342
    [Abstract] [Full Text] [Related]

  • 8. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.
    Cancer Res; 2002 Nov 01; 62(21):6304-11. PubMed ID: 12414661
    [Abstract] [Full Text] [Related]

  • 9. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 01; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.
    Kocić J, Santibañez JF, Krstić A, Mojsilović S, Ilić V, Bugarski D.
    Int J Biochem Cell Biol; 2013 Feb 01; 45(2):464-75. PubMed ID: 23183001
    [Abstract] [Full Text] [Related]

  • 11. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
    Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2003 Nov 01; 52(5):391-8. PubMed ID: 12908082
    [Abstract] [Full Text] [Related]

  • 12. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
    Huang DY, Chao Y, Tai MH, Yu YH, Lin WW.
    J Biomed Sci; 2012 Mar 30; 19(1):35. PubMed ID: 22462553
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, Fidler IJ, Bar-Eli M.
    Clin Cancer Res; 2002 Nov 30; 8(11):3584-91. PubMed ID: 12429650
    [Abstract] [Full Text] [Related]

  • 14. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May 30; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

  • 15. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
    Cancer Res; 2005 Sep 15; 65(18):8423-32. PubMed ID: 16166321
    [Abstract] [Full Text] [Related]

  • 17. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
    Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY.
    Oncogene; 2001 Jun 28; 20(29):3845-56. PubMed ID: 11439348
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 28; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 19. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
    Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S.
    J Clin Endocrinol Metab; 2003 Apr 28; 88(4):1889-96. PubMed ID: 12679488
    [Abstract] [Full Text] [Related]

  • 20. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
    Simon C, Juarez J, Nicolson GL, Boyd D.
    Cancer Res; 1996 Dec 01; 56(23):5369-74. PubMed ID: 8968087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.